A recent study has shown that RS-504393, a selective antagonist of the chemokines C-C motif receptor 2 (CCR2), reduced the expression of P2X4R in the spinal cord and relieved bone cancer pain, rendering P2X4R a potential target for cancer pain therapy (76). The gene discussed is P2RX4; the disease is cancer.